PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2017

Abstract – Guideline Objective: 

As part of a regular monitoring program recommended by the PEBC, a systematic review of recent evidence on the use of PET in patients with cancer, sarcoidosis, or epilepsy is conducted every six months. This report is intended to be a high-level, brief summary of the identified evidence, and not a detailed evaluation of its quality and relevance.

Abstract – Patient Population: 

Adult and pediatric patients with suspected or diagnosed cancer(s), sarcoidosis, or epilepsy (The cancer is not limited to those cancers with approved or Ontario Health Insurance (OHIP) insured services).

Abstract – Intended Guideline Users: 

Ontario PET Steering Committee

Abstract – Research Questions:

What is the role of positron emission tomography (PET) in the clinical management of patients with cancer, sarcoidosis, or epilepsy with respect to:

• Diagnosis and staging
• Assessment of treatment response
• Detection and restaging of recurrence
• Evaluation of metastasis

Outcomes of interest are survival, quality of life, prognostic indicators, time until recurrence, safety outcomes (e.g., avoidance of unnecessary surgery), and change in clinical management.